Jubilant Pharmova Limited Share Price NSE India S.E.
Equities
JUBLPHARMA
INE700A01033
Pharmaceuticals
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
674.2 INR | -1.71% | -1.01% | +23.60% |
04-25 | Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA | MT |
04-17 | Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility | MT |
Sales 2022 | 61.3B 735M 58.85B | Sales 2023 | 62.82B 753M 60.3B | Capitalization | 44.42B 532M 42.64B |
---|---|---|---|---|---|
Net income 2022 | 4.14B 49.59M 3.97B | Net income 2023 | -610M -7.31M -586M | EV / Sales 2022 | 1.37 x |
Net Debt 2022 | 22.03B 264M 21.15B | Net Debt 2023 | 26.44B 317M 25.38B | EV / Sales 2023 | 1.13 x |
P/E ratio 2022 |
14.9
x | P/E ratio 2023 |
-72.8
x | Employees | 5,778 |
Yield 2022 |
1.29% | Yield 2023 |
1.79% | Free-Float | 36.33% |
1 day | -1.71% | ||
1 week | -1.01% | ||
Current month | +18.30% | ||
1 month | +18.30% | ||
3 months | +16.91% | ||
6 months | +69.72% | ||
Current year | +23.60% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 22/05/17 | |
Chief Executive Officer | 37 | 22/05/17 | |
Arvind Chokhany
DFI | Director of Finance/CFO | 52 | 31/03/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 31/12/81 | |
Chairman | 71 | 20/06/78 | |
Chief Executive Officer | 46 | 22/05/17 |
Date | Price | Change | Volume |
---|---|---|---|
30/04/24 | 674.2 | -1.71% | 177,612 |
29/04/24 | 685.9 | +0.77% | 126,926 |
26/04/24 | 680.6 | +0.42% | 238,359 |
25/04/24 | 677.8 | -0.66% | 216,020 |
24/04/24 | 682.3 | -0.44% | 98,798 |
Delayed Quote NSE India S.E., April 30, 2024 at 12:42 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+32.80% | 704B | |
+28.59% | 577B | |
-3.65% | 348B | |
+17.97% | 327B | |
+4.80% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.28% | 147B |
- Stock Market
- Equities
- JUBLPHARMA Stock
- JUBLPHARMA Stock